Medical News / Reporting from ESC 2023: New Evidence, Guidelines Support Mavacamten Use in Hypertrophic Cardiomyopathy

At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its role in obstructive hypertrophic cardiomyopathy (HCM). Pushing it onto centerstage was a pair of studies detailing the long-term effects of use, a single study demonstrating the benefit among patients in China, and a new guideline update from the ESC focused on cardiomyopathies, which included Class IIa recommendations for mavacamten. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more
Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more
For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more
For endocrinologists and the diabetes care team, GLP-1 receptor agonists have been a familiar face for ... read more